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Physico-chemical characterization of biomacromolecule magnetoferritin in terms of 18 
morphology, structural and magnetic properties shows that iron oxides can be efficiently 19 
loaded into apoferritin molecules, preserving its native, bio-compatible structure. At the same 20 
time, such loading affects the morphology of the protein shell.  21 
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Natural ferritin is the iron-storage protein of animals, plants, and bacteria. It is a spherical 25 
biomacromolecule of external diameter about 12 nm composed of 24 protein subunits 26 
arranged as a hollow sphere of approximately 8 nm in diameter. Inside the sphere, iron is 27 
stored in the ferric oxidation state as complex molecule with a crystallographic structure 28 
similar to the mineral ferrihydrite [1]. By a suitable chemical process, magnetic iron oxide 29 
nanoparticles (Fe3O4, γ−Fe2O3) can be synthesized in the empty protein shell of ferritin, i.e. 30 
apoferritin, forming a biocompatible ferrofluid, called magnetoferritin [2,3]. The problem of 31 
toxicity and side effects of magnetic nanoparticles in organs and tissues is minimized due to 32 
the protein nature of this material, which is important for many possible applications in cell 33 
labeling, biological separation and clinical practice. Their magnetic properties, based on their 34 
inducible magnetization, allow them to be heated by externally applied AC magnetic field. It 35 
makes them attractive for many applications, ranging from various magnetic separation 36 
techniques and contrast enhancing agents for MRI to magnetic hyperthermia [4, 5]. 37 
Magnetoferritin is a promising compound which can be used as a drug carrier; the protein 38 
shell is able bind to tumor cells via transferin receptor 1 (TfR1) [6] and the drug can be bound 39 
to the protein subunit. In addition to biocompatibility, another advantage for biotechnological 40 
applications of magnetoferritin is a relatively short time of controlled synthesis [7, 8]. 41 
 The main interest of the present study is associated with understanding of certain diseases 42 
development mechanism that is in a close relationship with the iron metabolism and iron 43 
storage protein, ferritin [9]. In healthy organisms, ferritin is able to store up to 4500 Fe atoms 44 
in a ferrihydrite-like mineral core [10]. Many researchers confirmed the presence of magnetite 45 
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nanoparticles inside pathological tissues [11, 12] which is related to the Fe2+ ions 46 
accumulation and defects in the normal storage function of ferritin [13]. This indicates the 47 
transformation of ferrihydrite to magnetite and formation of biogenic magnetoferritin. The 48 
precise mode of such transformation regulated by the biochemistry of organisms (presence of 49 
specific enzymes, bio-complexes, etc.) has not been determined yet. Therefore, in this 50 
research, magnetoferritin prepared by in vitro chemical synthesis was used as a model system 51 
of pathological ferritin. Structural studies of ferritin and magnetoferritin would be useful to 52 
elucidate the structural changes of ferritin shell disruption or aggregation which is observed in 53 
development of many cancer or neurodegenerative diseases [14, 15].  54 
 In this paper, magnetoferritin prepared by controlled chemical synthesis, is the subject 55 
of structure-sensitive physical characterization techniques, such as dynamic light scattering 56 
(DLS), transmission electron microscopy (TEM), small-angle neutron and X-ray scattering 57 
(SANS, SAXS) and SQUID magnetometry. 58 
 Magnetoferritin was prepared in the way described in our previous work [16]. 59 
 The zeta potential of the studied apoferritin and magnetoferritin at comparable 60 
concentration 2.11 mg/ml and 2.36 mg/ml was -25.5 mV, -21.9 mV respectively. The results 61 
confirm the negative charge of the molecule and its good stability. The hydrodynamic 62 
diameter of magnetoferritin molecules was measured and compared with that of apoferritin by 63 
dynamic light scattering technique with protein concentration of 0.3 g.L-1 in both solutions 64 
(Fig. 1.).  65 
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 66 
Fig. 1.The size distributions of apoferritin and magnetoferritin as revealed by DLS 67 
 68 
Generally, the hydrodynamic diameter is larger than the theoretical size because it 69 
indicates the effective size of the hydrated/solvated molecule. In comparison with apoferritin 70 
hollow sphere (<DHYDR> = 14.14 nm), the hydrodynamic diameter of magnetoferritin 71 
increases (<DHYDR> = 19.54 nm). Such increase can be related to a deformation of the 72 
particles upon loading with iron oxide and to the presence of some fraction of aggregated 73 
particles. 74 
 Transmission electron microscopy showed presence of well-defined rounded 75 
nanocrystallites (Fig. 2.) with average diameter <D> of 5 nm. 76 
 77 
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 78 
Fig. 2. TEM image of magnetoferritin 79 
 80 
Electron diffraction of magnetoferritin samples confirms the face-centered cubic crystalline 81 
structure of the ferrous phase but it is not possible distinguish between magnetite (Fe3O4) or 82 
maghemite (γ−Fe2O3). More information can be obtained by magneto-optical birefringence or 83 
Faraday rotation studies as was shown in our recent works [17,18].  84 
 Small-angle neutron scattering measurements were performed at the Yellow 85 
Submarine instrument operating at the Budapest Neutron Centre [19]. Samples were prepared 86 
by redispersing apoferritin and magnetoferritin in D2O from dry powder to form 2 weight 87 
percent solution. 88 
 89 
 90 
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 92 
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 98 
Fig. 3. SANS data of magnetoferritin and apoferritin dispersions in D2O. The solid lines are 99 
model fits of a spherical shell to the apoferritin data and the same model including aggregated 100 
particles for the magnetoferritin data. 101 
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 114 
Fig. 4. Field dependence of magnetoferritin magnetization measured at room temperature. 115 
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In Fig. 3. the scattering data from pure (unloaded) apoferritin is compared to the scattering of 117 
magnetoferritin. For both solutions, the minima and maxima characteristic to the spherical 118 
shell form factor of apoferritin are seen. For magnetoferritin the oscillations are less 119 
pronounced, indicating that the spherical form of the protein is only partly preserved. The 120 
relative weakening of the characteristic shell structure is attributed to deformation of the 121 
protein shell upon loading, leading to decrease of the spherical symmetry of the molecules. 122 
The increase of the scattering intensity at small q values shows that a fraction of the 123 
molecules aggregate to loose objects of sizes larger than 200 nm. The experimental data were 124 
modeled using the hollow spherical shell model of apoferritin and aggregated spherical shell 125 
particles for the case of magnetoferritin. The solution contains both aggregated and non-126 
aggregated particles, and the used modeling could not distinguish these populations, therefore 127 
the fraction of aggregated particles could not be extracted from the data. Small-angle X-ray 128 
scattering data, taken using a laboratory setup, confirmed that the aggregates contain iron 129 
oxide. 130 
 Magnetic properties of magnetoferritin were investigated using SQUID magnetometer 131 
in magnetic fields up to 4 000 kA.m-1. The samples show superparamagnetic behavior without 132 
hysteresis at room temperature (Fig. 4). Using the particle size as obtained by TEM, and 133 
assuming magnetite, the saturation magnetization of 8 A.m2.kg-1 was calculated. The 134 
observed magnetization is by an order of magnitude lower than this value, indicating that the 135 
magnetic core of magnetoferritin presumably consists of mixed hematite and magnetite. The 136 
magnetization curves measured at 2K below blocking temperature (Tb = 26 K) showed the 137 
hysteresis with coercive field of 20.0 kA.m-1. The magnetization measured at 5 K undergoes a 138 
slow approach to saturation at field which we can achieve.  139 
 140 
In conclusion, the synthesized materials show superparamagnetic behavior, the 141 
structure as determined by TEM and scattering shows that magnetic nanoparticles are 142 
confined in the spherical protein shell, with particle diameters about 5 nm, thus not filling the 143 
entire available space. The protein structure slightly changes upon loading, this change can be 144 
attributed to the effect of iron oxides binding and ordering inside the protein cavity of 145 
magnetoferritin. Further experiments, for example, contrast variation SANS methods would 146 
give more detailed information concerning the protein and the magnetic structure of 147 
magnetoferritin with different loading factors, to reveal how the iron oxides affect protein 148 
conformation. Clarification of these effects could have a major impact in biomedicine for 149 
understanding the role of magnetite in connection with aggregation process in the 150 
development of neurodegenerative diseases. 151 
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